CBS 2019
CBSMD教育中心
中 文

药物涂层球囊

Abstract

Recommended Article

Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review Percutaneous Treatment and Outcomes of Small Coronary Vessels: A SCAAR Report Benefits with drug-coated balloon as compared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: a comprehensive meta-analysis of 45 randomized trials Survival After Coronary Revascularization With Paclitaxel-Coated Balloons 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis

Review Article2018 Jan 1;3(1):87.

JOURNAL:JAMA Cardiol. Article Link

Coronary Computed Tomography–Based Fractional Flow Reserve A Rapidly Developing Field

Baumann S, Renker M, Schoepf UJ. Keywords: Coronary Computed Tomography; Fractional Flow Reserve

ABSTRACT


Coronary computed tomography angiography (cCTA)–based fractional flow reserve (FFR-CT) is an evolving technology of disruptive potential to noninvasively determine the hemodynamic significance of a coronary artery stenosis. The systematic review by Cook et alprovides an excellent overview on the status of this innovative method. In their Methods section, the authors mention the FFR-CT algorithm approved by the US Food and Drug Administration in late 2014. However, technology and evidence in this field are rapidly evolving, which adds new facets to their discussion.